SCHEMBL4154433

SCHEMBL4154433

Cc1nc(-c2cccnc2)sc1-c1ccnc(Nc2cccc(CN)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.54
BCR P11274 6/20 0.54
CDK2 P24941 11/20 0.53
CDK4 P11802 9/20 0.53
SRC P12931 3/20 0.52
EGFR P00533 3/20 0.52
PRKACA P17612 1/20 0.52
PRKACG P22612 1/20 0.52
PRKACB P22694 1/20 0.52
CCNT1 O60563 3/20 0.49
CDK1 P06493 3/20 0.49
CCNB1 P14635 3/20 0.49
CCNA2 P20248 3/20 0.49
CDK7 P50613 3/20 0.49
CDK9 P50750 3/20 0.49
CCNH P51946 3/20 0.49
CCNA1 P78396 2/20 0.49
PRKCA P17252 3/20 0.49
PRKCD Q05655 2/20 0.49
KIT P10721 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159128 0.86 CDK4 (0.56) ABL1BCRCDK2CDK4SRC
SCHEMBL27720404 0.85 CDK2 (0.67) ABL1BCRCDK2CDK4EGFR
SCHEMBL28765387 0.84 ABL1 (0.50) ABL1BCRCDK2CDK4SRC
SCHEMBL4169340 0.84 CDK2 (0.74) ABL1CDK2CDK4CCNT1CDK1
SCHEMBL7461095 0.84 ABL1 (0.72) ABL1BCRSRCEGFRPRKACA
SCHEMBL2075737 0.83 CDK2 (0.72) ABL1CDK2CDK4PRKACACCNT1
SCHEMBL2073975 0.82 CDK2 (0.62) ABL1CDK2CDK4PRKACACCNT1
SCHEMBL6156799 0.81 ABL1 (0.73) ABL1BCRCDK2CDK4SRC
SCHEMBL12278950 0.80 CDK2 (0.51) ABL1BCRCDK2CDK4EGFR
SCHEMBL6156440 0.80 CDK2 (0.67) ABL1BCRCDK2CDK4EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 ABL1 59/4885BCR 1047/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.